A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07239570 on ClinicalTrials.gov · last registry update 2025-11-20
Recruiting now, toward 125 participants. Due to report June 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Chronic eGFR slope. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for chronic kidney disease, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Peter Rossing
- Sponsor type
- Other
- Enrollment
- 125
- Started
- 2025-06-20
- Primary completion
- 2028-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Chronic eGFR slope
Conditions studied
Chronic Kidney Disease(CKD)
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.